Study S002741

Real World Evidence Clinical Utility Study of KidneyIntelX in Patients With Type 2 Diabetes and Chronic Kidney Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04802395
Study type: OBSERVATIONAL
Status: RECRUITING
Enrollment: 10000
Start: 2021-03-02
Primary completion: 2026-12-01
Lead sponsor: Renalytix AI, Inc.
Conditions: Chronic Kidney Diseases; Diabetic Kidney Disease
Interventions: DIAGNOSTIC_TEST:KidneyIntelX
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Referrals [6 Months]
Statins and or ACEi/ARB [6 Months]
HbA1c [6 Months]
SGLT2/ GLP1 [6 Months]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0024004	A Real-World Precision Medicine Program Including the KidneyIntelX Test Effectively Changes Management Decisions and Outcomes for Patients With Early-Stage Diabetic Kidney Disease. Tokita J, Journal of primary care & community health	2024	Nonrandomized study	PMID 38185870 DOI	cites ClinicalTrials.gov:NCT04802395
R0050114	14-LB: Clinical Utility of KidneyIntelX on Patients with Early-Stage Diabetic Kidney Disease—A Real-World Evidence Study Joji Erik Tokita, Diabetes	2022	Nonrandomized study	DOI	cites ClinicalTrials.gov:NCT04802395